Evidence map›Paper›PMID 39108673›Full record

ArticleFrontiers in cardiovascular medicine2024

The synergistic effect of the atherogenic index of plasma and hyperuricemia on the prediction of coronary chronic total occlusion lesion: an observational cross-sectional study.

HongYa Han, XiaoLi Liu, Qi Zhao, ZhiJian Wang, Yan Sun, Xiaoteng Ma, MengChen Li, HanYing Ma, YuYang Liu, DongMei Shi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

HongYa HanDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
XiaoLi LiuDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
Qi ZhaoDepartment of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ZhiJian WangDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
Yan SunDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
Xiaoteng MaDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
MengChen LiDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
HanYing MaDepartment of General Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
YuYang LiuDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
DongMei ShiDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
YuJing ChengDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.
YuJie ZhouDepartment of Cardiology, Beijing Anzhen Hospital, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The atherogenic index of plasma (AIP) and hyperuricemia (HUA) have been shown to be closely associated with morbidity and mortality of coronary artery disease. However, studies targeting predictive value of AIP and HUA for chronic total occlusion (CTO) lesions are still lacking. Methods: In total, 5,238 patients meeting the eligibility criteria were recruited in this analysis. CTO was defined as the condition of lesions without forward blood flow and with over three months of occlusion time. AIP was calculated as log10 [triglycerides (mmol/L)/high-density lipoprotein cholesterol (mmol/L)]. HUA was defined based on sex-specific criteria: serum uric acid 420 and 360 μmol/L for males and females, respectively. Results: CTO lesions were presented in 907 (17.3%) patients. Compared with patients showing lower AIP levels and non-HUA, the CTO lesion risks increased by 5.225 and 2.765 times in patients with higher AIP levels and HUA. Patients with AIP >0.15 and HUA exhibited the greatest CTO incidence (odds ratio 11.491; 95% confidence interval 9.019-14.641, Conclusion: Patients having higher AIP levels and HUA exhibited the highest CTO incidence, in comparison with patients who have the increased single index. AIP combined with HUA displayed significant synergistic effect on the prediction of CTO lesion.

Indexed as

atherogenic index of plasmachronic total occlusioncoronary artery diseasehyperuricemiaprediction

Identifiers

PMID39108673
PMCPMC11300285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.